Filon Francesca Larese, Lazzarato Ilaria, Patriarca Emilia, Iavernig Thomas, Peratoner Alberto, Perri Giuseppe, Ponis Giuliano, Rocco Giulio, Cegolon Luca
Unit of Occupational Medicine, Department of Medical Surgical & Health Sciences, University of Trieste, 34129 Trieste, Italy.
Unit of Occupational Medicine, University Health Agency Giuliano-Isontina (ASUGI), 34129 Trieste, Italy.
Vaccines (Basel). 2022 Sep 27;10(10):1616. doi: 10.3390/vaccines10101616.
Background. Allergic patients may develop reactions following COVID-19 vaccination more frequently than non-allergic individuals. The aim of our study was to assess the risk of reactions in high-risk allergic patients vaccinated for COVID-19 at the University Health Agency Giuliano-Isontina (ASUGI) of Trieste (northeastern Italy). Methods. Patients were considered at high risk for allergic reactions in case of: prior anaphylactic reaction to any drug/vaccine; multiple drug allergy; intolerance to polyethylene glycol (PEG) or polysorbate 80 (PS80) containing drugs; and mast cell disorders. High-risk allergic patients were immunized in hospital by a dedicated allergy team supported by resuscitation staff. Patients were interviewed over the phone one month after vaccination to complete a structured questionnaire investigating signs and symptoms developed after immunization. Results. From March 2021 to February 2022, 269 patients with a history of severe allergic reactions were assessed, of whom 208 (77.3%) eventually received COVID-19 vaccination, 50 (18.6%) refused to be immunized, 10 (3.7%) were deferred for medical reasons and one was declared exempted due to testing positive for PS80. Mild reactions (urticaria, angioedema, rhinitis, erythema) to COVID-19 vaccines were reported by 30.3% of patients, 8.7% within 4 h and 21.6% > 4 h after immunization. No anaphylactic events were observed. Although they were 80 times (3.8%) more prevalent than in COVID-19 vaccinees from the general population (0.047%), vaccine allergic reactions in high-risk patients were mainly mild and late, more likely affecting women (OR = 3.05; 95% CI 1.22−7.65). Conclusions. High-risk allergic patients with urticaria and angioedema may experience mild flare-ups of mast cell activation-like symptoms following COVID-19 vaccination, supporting antihistamine premedication before vaccination and to be continued for one week afterwards.
背景。与非过敏个体相比,过敏患者在接种新冠病毒疫苗后更易出现不良反应。我们研究的目的是评估在意大利东北部的里雅斯特朱利亚诺 - 伊松蒂纳大学健康机构(ASUGI)接种新冠病毒疫苗的高危过敏患者出现不良反应的风险。方法。若患者存在以下情况,则被视为过敏反应高危人群:既往对任何药物/疫苗有过敏反应;多种药物过敏;对含聚乙二醇(PEG)或聚山梨酯80(PS80)的药物不耐受;以及肥大细胞疾病。高危过敏患者在医院由专业过敏团队进行免疫接种,并由复苏人员提供支持。接种疫苗一个月后通过电话对患者进行访谈,以完成一份结构化问卷,调查免疫接种后出现的体征和症状。结果。2021年3月至2022年2月,对269例有严重过敏反应病史的患者进行了评估,其中208例(77.3%)最终接种了新冠病毒疫苗,50例(18.6%)拒绝接种,10例(3.7%)因医学原因推迟接种,1例因PS80检测呈阳性而被宣布豁免接种。30.3%的患者报告了对新冠病毒疫苗的轻度反应(荨麻疹、血管性水肿、鼻炎、红斑),8.7%在免疫接种后4小时内出现,21.6%在免疫接种后4小时后出现。未观察到过敏反应事件。尽管高危患者的疫苗过敏反应比普通人群中接种新冠病毒疫苗的人高出80倍(3.8%对比0.047%),但主要为轻度且出现较晚,更易影响女性(比值比 = 3.05;95%置信区间1.22 - 7.65)。结论。有荨麻疹和血管性水肿的高危过敏患者在接种新冠病毒疫苗后可能会出现轻度的肥大细胞活化样症状发作,这支持在接种疫苗前进行抗组胺药预处理,并在接种后持续一周。